AMP-activated protein kinase slows D2 dopamine autoreceptor desensitization in substantia nigra neurons

Neuropharmacology. 2019 Nov 1:158:107705. doi: 10.1016/j.neuropharm.2019.107705. Epub 2019 Jul 10.

Abstract

Dopamine neurons in the substantia nigra zona compacta (SNC) are well known to express D2 receptors. When dopamine is released from somatodendritic sites, activation of D2 autoreceptors suppresses dopamine neuronal activity through activation of G protein-coupled K+ channels. AMP-activated protein kinase (AMPK) is a master enzyme that acts in somatic tissues to suppress energy expenditure and encourage energy production. We hypothesize that AMPK may also conserve energy in central neurons by reducing desensitization of D2 autoreceptors. We used whole-cell patch-clamp recordings to study the effects of AMPK activators and inhibitors on D2 autoreceptor-mediated current in SNC neurons in midbrain slices from rat pups (11-23 days post-natal). Slices were superfused with 100 μM dopamine or 30 μM quinpirole for 25 min, which evoked outward currents that decayed slowly over time. Although the AMPK activators A769662 and ZLN024 significantly slowed rundown of dopamine-evoked current, slowing of quinpirole-evoked current required the presence of a D1-like agonist (SKF38393). Moreover, the D1-like agonist also slowed the rundown of quinpirole-induced current even in the absence of an AMPK activator. Pharmacological antagonist experiments showed that the D1-like agonist effect required activation of either protein kinase A (PKA) or exchange protein directly activated by cAMP 2 (Epac2) pathways. In contrast, the effect of AMPK on rundown of current evoked by quinpirole plus SKF38393 required PKA but not Epac2. We conclude that AMPK slows D2 autoreceptor desensitization by augmenting the effect of D1-like receptors.

Keywords: AMP kinase; D1 receptor; D2 autoreceptor; Desensitization; Dopamine; Substantia nigra.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
  • AMP-Activated Protein Kinases / drug effects
  • AMP-Activated Protein Kinases / metabolism*
  • Animals
  • Autoreceptors / drug effects
  • Autoreceptors / metabolism*
  • Biphenyl Compounds
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Dopamine / pharmacology*
  • Dopamine Agonists / pharmacology*
  • Enzyme Activators / pharmacology
  • Guanine Nucleotide Exchange Factors / metabolism
  • Neurons / drug effects
  • Neurons / metabolism*
  • Pars Compacta / cytology*
  • Patch-Clamp Techniques
  • Pyrimidines / pharmacology
  • Pyrones / pharmacology
  • Quinpirole / pharmacology*
  • Rats
  • Receptors, Dopamine D2 / drug effects
  • Receptors, Dopamine D2 / metabolism*
  • Thiophenes / pharmacology

Substances

  • Autoreceptors
  • Biphenyl Compounds
  • Dopamine Agonists
  • Enzyme Activators
  • Guanine Nucleotide Exchange Factors
  • Pyrimidines
  • Pyrones
  • Rapgef4 protein, rat
  • Receptors, Dopamine D2
  • Thiophenes
  • ZLN024
  • Quinpirole
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • Cyclic AMP-Dependent Protein Kinases
  • AMP-Activated Protein Kinases
  • 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile
  • Dopamine